article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Worldwide obesity rates have tripled since 1975, with 650 million adults obese in 2016, according to the World Health Organization. It has to persuade patients to sign up for some heinous side effects. In 2019, the OECD declared that developed countries’ plans to tackle the problem largely failed.

article thumbnail

Biogen: This train wreck was due

World of DTC Marketing

When George Scangos resigned in 2016, he must have known that the future was bleak. The MS community, which is very active on social media, complained about the side effects of Biogen’s drug while praising new competitors’ drugs. The company was riding high on their MS drugs, but the competition was on the way.

Training 231
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE guidance recommends olaparib for breast and prostate cancers

European Pharmaceutical Review

Additionally, this means NICE has now made positive recommendations in all 19 of its appraisals of breast cancer treatments since 2016. For adults with advanced prostate cancer it can also mean delaying chemotherapy and its associated side effects,” she added.

article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty side effects. After the CEO departed the sinking ship, new management pinned all their hopes on the Biogen drug for Alzheimer’s.

FDA 187
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its orally-administered therapy Evrysdi (risdiplam) in 2020. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1

article thumbnail

Aiming for ‘Magic Bullets’ in Medicine: Are We Shooting Ourselves in the Foot?

Clarivate

A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] 6] As many pathogenetic targets have multiple physiological functions, highly specific ‘magic bullets’ may impact multiple cellular pathways simultaneously, causing unintended side effects.7 Chin J Cancer.

article thumbnail

Takeda claims first phase 3 win in rare disease cTTP

pharmaphorum

In the phase 3 trial, TAK-755 reduced the incidence of thrombocytopenia events by 60% compared to plasma-based treatment and was much better tolerated, with less than 9% of patients on Takeda’s drug reporting side effects compared to almost half (48%) of those on standard therapy.